The US Food and Drug Administration is holding the line on requiring reliable data supporting an OTC switch application no matter how much and how often the sponsor describes the numerous public health benefits of expanding access to a daily oral contraceptive.
Agency officials, on 9 May during the first day of a two-day advisory panel meeting conducted online, also heard almost...







